AM-1476 is under clinical development by AnaMar and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AM-1476’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 17 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 17 Feb 2022 increased AM-1476’s Phase Transition Success Rate (PTSR) for Systemic Sclerosis (Scleroderma).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AM-1476 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AM-1476 overview

AM-1476 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis, liver fibrosis, cardiac fibrosis, fibrotic tumors and graft-versus-host disease. The therapeutic candidate is administered through oral route. It acts by targeting 5-hydroxytryptamine receptor 2B (5-HT-2B).

AnaMar overview

AnaMar, a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. It develops drug candidates from several chemical classes on the receptors and shows potent anti-inflammatory and pain relieving effects. It carries out research to discover, validate, screen and optimize new disease-modifying drugs to target novel cellular pathways and suppress inflammation, pain and fibrosis. AnaMar’s pipeline projects comprise AMAP102, AM1030-cream, Mitra and Sting. The company develops 5-HT2B receptor antagonists with potential use in a wide range of human diseases. AnaMar is headquartered in Lund, Sweden.

Quick View AM-1476 LOA Data

Report Segments
  • Innovator
Drug Name
  • AM-1476
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Immunology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.